Eagle Pharmaceuticals (EGRX) Competitors $0.65 -0.05 (-7.14%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EGRX vs. ACHL, ANEB, RLYB, DRRX, VTVT, LTRN, CARM, PASG, NXTC, and VRCAShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Achilles Therapeutics (ACHL), Anebulo Pharmaceuticals (ANEB), Rallybio (RLYB), DURECT (DRRX), vTv Therapeutics (VTVT), Lantern Pharma (LTRN), Carisma Therapeutics (CARM), Passage Bio (PASG), NextCure (NXTC), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Achilles Therapeutics Anebulo Pharmaceuticals Rallybio DURECT vTv Therapeutics Lantern Pharma Carisma Therapeutics Passage Bio NextCure Verrica Pharmaceuticals Eagle Pharmaceuticals (NASDAQ:EGRX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends. Which has more volatility and risk, EGRX or ACHL? Eagle Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Which has better valuation & earnings, EGRX or ACHL? Eagle Pharmaceuticals has higher revenue and earnings than Achilles Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEagle Pharmaceuticals$316.61M0.03$35.64MN/AN/AAchilles TherapeuticsN/AN/A-$69.67M-$1.65-0.64 Does the media favor EGRX or ACHL? In the previous week, Achilles Therapeutics had 3 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 6 mentions for Achilles Therapeutics and 3 mentions for Eagle Pharmaceuticals. Achilles Therapeutics' average media sentiment score of 0.48 beat Eagle Pharmaceuticals' score of 0.00 indicating that Achilles Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eagle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Achilles Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor EGRX or ACHL? Eagle Pharmaceuticals received 395 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 67.99% of users gave Eagle Pharmaceuticals an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote. CompanyUnderperformOutperformEagle PharmaceuticalsOutperform Votes41267.99% Underperform Votes19432.01% Achilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% Do insiders & institutionals have more ownership in EGRX or ACHL? 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is EGRX or ACHL more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat Achilles Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eagle PharmaceuticalsN/A N/A N/A Achilles Therapeutics N/A -47.24%-41.69% Do analysts rate EGRX or ACHL? Achilles Therapeutics has a consensus target price of $4.00, indicating a potential upside of 280.95%. Given Achilles Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Achilles Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryEagle Pharmaceuticals beats Achilles Therapeutics on 8 of the 14 factors compared between the two stocks. Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.45M$6.39B$5.06B$8.67BDividend YieldN/A8.04%5.06%4.06%P/E RatioN/A10.63100.7117.26Price / Sales0.03266.481,206.6171.28Price / Cash0.2053.4940.7536.36Price / Book0.049.306.325.87Net Income$35.64M$154.14M$119.47M$225.66M7 Day Performance-23.58%-9.49%-5.11%-1.34%1 Month Performance-18.71%-7.23%-3.21%1.00%1 Year Performance-92.47%30.70%32.43%25.27% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle Pharmaceuticals1.1313 of 5 stars$0.65-7.1%N/A-92.6%$8.45M$316.61M0.00134Analyst ForecastNews CoverageGap UpACHLAchilles Therapeutics2.546 of 5 stars$1.04-1.0%N/A+31.1%$42.73MN/A-0.65250Short Interest ↓News CoverageANEBAnebulo Pharmaceuticals3.1 of 5 stars$1.63+10.9%N/A-28.8%$42.27MN/A-5.094Short Interest ↓News CoverageGap UpRLYBRallybio3.3674 of 5 stars$1.01+1.0%N/A-57.5%$41.90M$299,000.00-0.6340DRRXDURECT3.2591 of 5 stars$1.33-0.7%N/A+65.6%$41.28M$8.55M-2.1880Analyst ForecastAnalyst RevisionVTVTvTv Therapeutics0.5417 of 5 stars$13.50-0.7%N/A+22.9%$40.64M$2.02M-1.979LTRNLantern Pharma0.874 of 5 stars$3.73-2.9%N/A-11.7%$40.17MN/A-2.1020Analyst RevisionCARMCarisma Therapeutics3.404 of 5 stars$0.96-4.7%N/A-65.5%$40.00M$14.92M-0.6220Short Interest ↓PASGPassage Bio3.0506 of 5 stars$0.64+4.2%N/A-17.3%$39.47MN/A-0.47130Analyst ForecastNews CoverageNXTCNextCure4.6484 of 5 stars$1.41+9.3%N/A+4.8%$39.45MN/A-0.6790Gap UpVRCAVerrica Pharmaceuticals4.6586 of 5 stars$0.85+2.1%N/A-73.7%$38.64M$5.12M-0.4640 Related Companies and Tools Related Companies ACHL Alternatives ANEB Alternatives RLYB Alternatives DRRX Alternatives VTVT Alternatives LTRN Alternatives CARM Alternatives PASG Alternatives NXTC Alternatives VRCA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EGRX) was last updated on 11/16/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EGRX Stock Alerts